METHOD FOR PREVENTING OSSEOUS-CARTILAGINOUS DESTRUCTION IN CASE OF RHEUMATOID ARTHRITIS Russian patent published in 2006 - IPC A61K31/196 A61K31/573 A61P29/00 

FIELD: medicine, rheumatology.

SUBSTANCE: the innovation deals with therapy with metothrexate at the dosage of 7.5 mg/wk in combination with small dosages of glucocorticosteroids, up to 10 mg/d against prednisolone. Metothrexate should be once introduced at the quantity of 7.5-20 mg/wk, glucocorticosteroids - once at 3 a.m. Therapy course lasts for bout 6 mo, not less followed by decreasing the dosage of glucocorticosteroids for 6 mo up to their complete refusal at keeping maintenance therapy with metothrexate. The innovation enables to achieve maximal increase of antidestructive action at any terms of disease due to preventing the development of new articular erosions and keeping the width of articular fissura at the most physiological scheme of glucocorticosteroids' intake.

EFFECT: higher efficiency of prophylaxis.

4 cl, 12 dwg, 4 ex, 3 tbl